This review provides an integrated and conceptual analysis of the HCC immune landscape, delineating the mechanistic drivers underlying immune suppression, summarizes current immune-based classification frameworks, and dissects the context-dependent functions of key immune cell populations in tumor progression.
Abstract
Despite transformative success in other solid tumors, immunotherapy has encountered a formidable barrier in hepatocellular carcinoma (HCC), a profoundly immunosuppressive tumor microenvironment (TME) that is predominantly "cold" and also exhibits remarkable heterogeneity across patients. This inter-patient variability in the immune context leads to different responses to treatment, limits clinical efficacy, and highlights the critical need for a deeper, systems-level understanding of the HCC immune landscape. This review provides an integrated and conceptual analysis of the HCC immune landscape. It delineates the mechanistic drivers underlying immune suppression, summarizes current immune-based classification frameworks, and dissects the context-dependent functions of key immune cell populations in tumor progression. Furthermore, this review surveys established TME-targeting therapies comprising primarily immune checkpoint blockade strategies and their clinically validated combinations, and highlights emerging agents and concepts under preclinical and early clinical development. By integrating mechanistic insights with immune classification and therapeutic advances, this review aims to provide a unifying framework to inform the rational design of next-generation immunotherapies for HCC.
This review synthesizes current evidence demonstrating that CCR8 is selectively upregulated on TI -Tregs across multiple solid tumor types, where its expression correlates with poor patient prognosis and resistance to immune checkpoint inhibitors (ICIs).
Together, current evidence indicates that MDSCs represent context-dependent therapeutic nodes, while functional reprogramming, spatially resolved profiling, and patient stratification may improve immunotherapy outcomes.
Lisichen Zhu, Hui Liu, Sihan Zhang et al.· Cancer Letters· 1 citation
Esophageal carcinoma (EC) remains one of the most lethal malignancies, with a five-year survival rate of only 15-25% in advanced stages. Although immunotherapy including immune checkpoint inhibitors (ICIs) and antibody-based therapies have improved clinical outcomes, durable responses are confined to a minority of pati...
Zheng-Lin He, Han-Ming Hao, Xin-Yang Shu et al.· Frontiers in Immunology· 0 citations
By integrating nanotechnology with immunotherapy, new opportunities arise to convert cold tumors into hot, immune-responsive phenotypes, thereby improving therapeutic efficacy and clinical outcomes.
M. Teiama, Asmaa Gohar, Mahmoud Amr et al.· Molecular Biomedicine· 0 citations
This review offers a comprehensive framework for understanding and surmounting immunosuppressive barriers in cancer therapy and develops systematic synergistic strategies such as multi-pathway checkpoint blockade, ADC-immunotherapy combinations, temporally and spatially optimized conventional therapies, and targeted ag...
Meng-Meng Liu, Yi-Chen Zhu, He-Miao Liang et al.· Frontiers in Immunology· 0 citations